These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 15012735)

  • 1. Atorvastatin in dyslipidaemia of the nephrotic syndrome.
    Valdivielso P; Moliz M; Valera A; Corrales MA; Sanchez-Chaparro MA; Gonzalez-Santos P
    Nephrology (Carlton); 2003 Apr; 8(2):61-4. PubMed ID: 15012735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis.
    Hufnagel G; Michel C; Vrtovsnik F; Queffeulou G; Kossari N; Mignon F
    Nephrol Dial Transplant; 2000 May; 15(5):684-8. PubMed ID: 10809811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure.
    Saltissi D; Westhuyzen J; Morgan C; Healy H
    Clin Exp Nephrol; 2006 Sep; 10(3):201-9. PubMed ID: 17009078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.
    Karalis DG; Ross AM; Vacari RM; Zarren H; Scott R
    Am J Cardiol; 2002 Mar; 89(6):667-71. PubMed ID: 11897207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
    Dart A; Jerums G; Nicholson G; d'Emden M; Hamilton-Craig I; Tallis G; Best J; West M; Sullivan D; Bracs P; Black D
    Am J Cardiol; 1997 Jul; 80(1):39-44. PubMed ID: 9205017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
    McKenney JM; McCormick LS; Weiss S; Koren M; Kafonek S; Black DM
    Am J Med; 1998 Feb; 104(2):137-43. PubMed ID: 9528731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype.
    Xu RX; Guo YL; Li XL; Li S; Li JJ
    Clin Exp Pharmacol Physiol; 2014 Jul; 41(7):475-81. PubMed ID: 24739131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity.
    Chan DC; Watts GF; Mori TA; Barrett PH; Beilin LJ; Redgrave TG
    Eur J Clin Invest; 2002 Jun; 32(6):429-36. PubMed ID: 12059988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beneficial effects of atorvastatin in the treatment of hyperlipidemia after renal transplantation.
    Demetriou D; Shabpar A; Böhmig G; Schmaldienst S; Hörl WH; Watschinger B
    Wien Klin Wochenschr; 2000 Apr; 112(8):358-61. PubMed ID: 10849941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia.
    Karpisek M; Stejskal D; Kotolova H; Kollar P; Janoutova G; Ochmanova R; Cizek L; Horakova D; Yahia RB; Lichnovska R; Janout V
    Eur J Clin Invest; 2007 Aug; 37(8):637-42. PubMed ID: 17635574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of low-dose atorvastatin on lipid levels and endothelial vascular function in patients with significant coronary artery stenosis.
    Kuryata OV; Yegorova YV
    Kardiol Pol; 2006 Jan; 64(1):44-8; discussion 49-50. PubMed ID: 16444629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term effect of atorvastatin in hypercholesterolaemic renal-transplant patients unresponsive to other statins.
    Romero R; Calviño J; Rodriguez J; Sánchez-Guisande D
    Nephrol Dial Transplant; 2000 Sep; 15(9):1446-9. PubMed ID: 10978406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluating the efficacy and tolerance of atorvastatin in hyperlipidemia in general practice (SWITCH Study)].
    Noseda G; Darioli R; Keller U; Mordasini R; Shokry A; Schaffhauser B; Riesen W
    Schweiz Med Wochenschr; 2000 Jun; 130(23):889-95. PubMed ID: 10897490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    Bays HE; Dujovne CA; McGovern ME; White TE; Kashyap ML; Hutcheson AG; Crouse JR;
    Am J Cardiol; 2003 Mar; 91(6):667-72. PubMed ID: 12633795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term (18-month) efficacy of atorvastatin therapy in type 2 diabetics at cardiovascular risk.
    Velussi M
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):29-35. PubMed ID: 12125227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
    McKenney JM; McCormick LS; Schaefer EJ; Black DM; Watkins ML
    Am J Cardiol; 2001 Aug; 88(3):270-4. PubMed ID: 11472706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.
    Athyros VG; Papageorgiou AA; Athyrou VV; Demitriadis DS; Kontopoulos AG
    Diabetes Care; 2002 Jul; 25(7):1198-202. PubMed ID: 12087019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.